Markets

Cancer immunotherapy biotech Unum Therapeutics files for an $86 million IPO

Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

The Cambridge, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol UNUM. Unum Therapeutics filed confidentially on November 3, 2017. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer immunotherapy biotech Unum Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More